Glycogen phosphorylase inhibitors.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/138955706777934991PMID 16918491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs

  2005cited by this paper
• 5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

  2005cited by this paper
• Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase Published, JLR Papers in Press, December 16, 2004. DOI 10.1194/jlr.M400436-JLR200

  2005cited by this paper
• Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle.

  2005cited by this paper
• Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors.

  2005cited by this paper
• Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.

  2004cited by this paper
• Regulation of glycogen metabolism in cultured human muscles by the glycogen phosphorylase inhibitor CP-91149.

  2004cited by this paper
• Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor.

  2004cited by this paper
• Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment

  2004cited by this paper
• A new class of glycogen phosphorylase inhibitors.

  2003cited by this paper
• Novel 3,4-dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a.

  2003cited by this paper
• Pharmacokinetics and anti‐hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4‐dideoxy‐1,4‐imino‐d‐ arabinitol, in glucagon‐challenged rats and dogs and in diabetic ob/ob mice

  2003cited by this paper
• Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression.

  2003cited by this paper
• Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors.

  2003cited by this paper
• A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity.

  2003cited by this paper
• Hepatic glucose metabolism in humans--its role in health and disease.

  2003cited by this paper
• Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.

  2003cited by this paper
• The binding of β‐ and γ‐cyclodextrins to glycogen phosphorylase b: Kinetic and crystallographic studies

  2003cited by this paper
• Integrated effects of multiple modulators on human liver glycogen phosphorylase a.

  2002cited by this paper
• Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.

  2002cited by this paper
• Diverse effects of two allosteric inhibitors on the phosphorylation state of glycogen phosphorylase in hepatocytes.

  2002cited by this paper
• The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors.

  2002cited by this paper
• Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus

  2001cited by this paper
• Global and societal implications of the diabetes epidemic

  2001cited by this paper
• Iminosugars: potential inhibitors of liver glycogen phosphorylase.

  2001cited by this paper
• Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug.

  2000cited by this paper
• Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice.

  2000cited by this paper
• Human liver glycogen phosphorylase inhibitors bind at a new allosteric site.

  2000cited by this paper
• Flavopiridol Inhibits Glycogen Phosphorylase by Binding at the Inhibitor Site*

  2000cited by this paper
• Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite.

  2000cited by this paper
• Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status

  2000cited by this paper
• Carcinogenesis of intestinal-type gastric cancer and colorectal cancer is commonly accompanied by expression of brain (fetal)-type glycogen phosphorylase.

  1999cited by this paper
• Glucose metabolism and the postprandial state

  1999cited by this paper
• Inhibition of glycogenolysis in primary rat hepatocytes by 1, 4-dideoxy-1,4-imino-D-arabinitol.

  1999cited by this paper
• Glucose and glycogen utilisation in myocardial ischemia - changes in metabolism and consequences for the myocyte

  1998cited by this paper
• Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI.

  1998cited by this paper
• The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 Å resolution and 100 K: The role of the water structure and its contribution to binding

  1998cited by this paper
• Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.

  1998cited by this paper
• Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI.

  1998cited by this paper
• Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.

  1998cited by this paper
• Autoregulation of hepatic glucose production.

  1998cited by this paper
• Hepatic gluconeogenic fluxes and glycogen turnover during fasting in humans. A stable isotope study.

  1997cited by this paper
• The structure of glycogen phosphorylase b with an alkyldihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor.

  1997cited by this paper
• Genetic deficiencies of the glycogen phosphorylase system

  1996cited by this paper
• Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection.

  1995cited by this paper
• McArdle's disease-muscle glycogen phosphorylase deficiency.

  1995cited by this paper
• Preischemic glycogen reduction or glycolytic inhibition improves postischemic recovery of hypertrophied rat hearts.

  1994cited by this paper
• Evolution of allosteric control in glycogen phosphorylase.

  1993cited by this paper
• Glycogen phosphorylase: control by phosphorylation and allosteric effectors

  1992cited by this paper
• Glucose analogue inhibitors of glycogen phosphorylase: the design of potential drugs for diabetes.

  1991cited by this paper
• The family of glycogen phosphorylases: structure and function.

  1989cited by this paper
• Failure of glycogen depletion to improve left ventricular function of the rabbit heart after hypothermic ischemic arrest.

  1988cited by this paper
• Analysis of an allosteric binding site: the nucleoside inhibitor site of phosphorylase alpha.

  1982cited by this paper
• X-ray crystallographic and kinetic studies of oligosaccharide binding to phosphorylase.

  1978cited by this paper
• Synergistic regulation of phosphorylase a by glucose and caffeine.

  1978cited by this paper

• Rapid and Effective Recovery of Oleanolic and Maslinic Acids from Olive Leaves Using SFE and pH-Zone Centrifugal Partition Chromatography

  2025cites this paper
• Huddling alleviates the decrease in glycogen and lipid content in the liver of Brandt’s vole caused by mild cold environment

  2025cites this paper
• Regulation of stress granule formation in human oligodendrocytes

  2024cites this paper
• Daniellia oliveri as a type 2 diabetes remedy: evidence from in-silico evaluation

  2024cites this paper
• Evaluation of chalcones as new glycogen phosphorylase inhibitors – an in-vitro and in-silico approach

  2024cites this paper
• Computational Insights into Novel Inhibitor N-(3-(tert-Butylcarbamoyl)-4-methoxyphenyl)-indole and Ingliforib Specific against GP Isoenzyme Dimers Interaction Mechanism

  2023cites this paper
• Protective effects of a novel glycogen phosphorylase inhibitor against cerebral ischemia-reperfusion injury in mice.

  2023cites this paper
• Current therapeutic targets and multifaceted physiological impacts of caffeine

  2023cites this paper
• Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer

  2023cites this paper
• Liver glycogen phosphorylase is upregulated in glioblastoma and provides a metabolic vulnerability to high dose radiation

  2022cites this paper
• Intracellular energy controls dynamics of stress-induced ribonucleoprotein granules

  2022cites this paper
• Anti-Diabetic Potential of Plant-Based Pentacyclic Triterpene Derivatives: Progress Made to Improve Efficacy and Bioavailability

  2021cites this paper
• Optimization and Validation of an In Vitro Standardized Glycogen Phosphorylase Activity Assay

  2021cites this paper
• Mechanochemical Synthesis and reactivity of 1,2,3-Triazole Carbohydrate Derivatives as Glycogen Phosphorylase Inhibitors.

  2020cites this paper
• Inhibition of brain-type glycogen phosphorylase ameliorates high glucose-induced cardiomyocyte apoptosis via Akt-HIF-1α activation.

  2020cites this paper
• Diabetic-induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus

  2020cites this paper
• Caffeine effects on systemic metabolism, oxidative-inflammatory pathways, and exercise performance.

  2020cites this paper
• Synthetic and Medicinal Attributes of 1,2,4-Triazole Derivatives

  2020cites this paper
• Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.

  2019cites this paper
• Novel 5‐(1‐aryl‐1H‐pyrazol‐3‐yl)‐1H‐tetrazoles as glycogen phosphorylase inhibitors: An in vivo antihyperglycemic activity study

  2019cites this paper
• The Impact of DJOS Surgery, a High Fat Diet and a Control Diet on the Enzymes of Glucose Metabolism in the Liver and Muscles of Sprague-Dawley Rats

  2019cites this paper
• The Activity of Phosphorylase Kinase Revisited

  2018cites this paper
• Understanding the Rate‐Limiting Step of Glycogenolysis by Using QM/MM Calculations on Human Glycogen Phosphorylase

  2018cites this paper
• Fibroblasts Mobilize Tumo r Cell Glycogen to Promote Proliferation and Metastasis Graphical Abstract Highlights

  2018cites this paper
• Ludwigia octovalvis (Jacq.) raven extract supplementation enhances muscle glycogen content and endurance exercise performance in mice

  2018cites this paper
• PHENOXYACETIC ACIDS AND ANALOGS

  2017cites this paper
• Effects of STZ-Induced Long-Term Hyperglycemia on the Lumbar Dorsal Gray Column of Albino Rats- A Histomorphometric Study

  2017cites this paper
• The 1,2,3-triazole ring as a bioisostere in medicinal chemistry.

  2017cites this paper
• Role of conventional oral antidiabetic drugs in management of type 2 diabetes mellitus

  2017cites this paper
• Novel Liver-targeted conjugates of Glycogen Phosphorylase Inhibitor PSN-357 for the Treatment of Diabetes: Design, Synthesis, Pharmacokinetic and Pharmacological Evaluations

  2017cites this paper
• 2-Oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors: Design, synthesis and structure-activity relationship study.

  2016cites this paper
• Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapy

  2016cites this paper
• Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.

  2016cites this paper
• Predicting Cross-Reactivity from Computational Studies for Pre-evaluation of Specific Hepatic Glycogen Phosphorylase Inhibitors - -insilico Screening of Drugs for Evaluating Specificity

  2015cites this paper
• Glycogen metabolism in cancer.

  2014cites this paper
• Synthesis of C-xylopyranosyl- and xylopyranosylidene-spiro-heterocycles as potential inhibitors of glycogen phosphorylase.

  2014cites this paper
• Antioxidant effects of maslinic acid in livers, hearts and kidneys of streptozotocin-induced diabetic rats: effects on kidney function

  2014cites this paper
• Regulated Exocytosis in Astrocytes is as Slow as the Metabolic Availability of Gliotransmitters: Focus on Glutamate and ATP.

  2014cites this paper
• Synthesis, screening and docking of small heterocycles as glycogen phosphorylase inhibitors.

  2014cites this paper
• Downregulation of Type II Diabetes Mellitus and Maturity Onset Diabetes of Young Pathways in Human Pancreatic Islets from Hyperglycemic Donors

  2014cites this paper
• Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose

  2014cites this paper
• Glutamate and ATP at the Interface of Metabolism and Signaling in the Brain

  2014cites this paper
• New synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles, nanomolar inhibitors of glycogen phosphorylase.

  2014cites this paper
• C-Glucopyranosyl-1,2,4-triazoles As New Potent Inhibitors of Glycogen Phosphorylase.

  2013cites this paper
• Synthesis and evaluation of C8-substituted 4.5-spiro lactams as Glycogen Phosphorylase a inhibitors

  2013cites this paper
• Synthesis of substituted 2-(β-D-glucopyranosyl)-benzimidazoles and their evaluation as inhibitors of glycogen phosphorylase.

  2013cites this paper
• The glycogen phosphorylase inhibitor 2-(3-benzylamino-2-oxo-1,2-dihydropyridin-1-yl)-N-(3,4-dichlorobenzyl)acetamide.

  2013cites this paper
• Synthesis, enzyme kinetics and computational evaluation of N-(β-D-glucopyranosyl) oxadiazolecarboxamides as glycogen phosphorylase inhibitors.

  2013cites this paper
• The pentacyclic triterpenoids in herbal medicines and their pharmacological activities in diabetes and diabetic complications.

  2013cites this paper
• Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase.

  2012cites this paper
• Intramolecular cyclization of alkoxyaminosugars: access to novel glycosidase inhibitor families.

  2012cites this paper
• Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.

  2011cites this paper
• Identification of pentacyclic triterpenes derivatives as potent inhibitors against glycogen phosphorylase based on 3D-QSAR studies.

  2011cites this paper
• Maslinic acid, a natural inhibitor of glycogen phosphorylase, reduces cerebral ischemic injury in hyperglycemic rats by GLT‐1 up‐regulation

  2011cites this paper
• Dynamic monitoring of cytosolic glucose in single astrocytes

  2011influential citation
• Effect of glucopyranosylidene-spiro-thiohydantoin on glycogen metabolism in liver tissues of streptozotocin-induced and obese diabetic rats.

  2011cites this paper
• Glucose derived inhibitors of glycogen phosphorylase

  2011cites this paper
• Current therapies and emerging drugs in the pipeline for type 2 diabetes.

  2011cites this paper
• A rapid, one-pot, microwave-influenced synthesis of spiro-2,5-diketopiperazines via a cascade Ugi/6-exo-trig aza-Michael reaction.

  2011cites this paper
• Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases.

  2011cites this paper
• Recent advances in the allosteric inhibition of glycogen phosphorylase.

  2010cites this paper
• Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.

  2010cites this paper
• Prolonged Inhibition of Glycogen Phosphorylase in Livers of Zucker Diabetic Fatty Rats Models Human Glycogen Storage Diseases

  2010cites this paper
• The prototype of glycogen phosphorylase.

  2010cites this paper
• Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors.

  2010cites this paper
• Physiological control of liver glycogen metabolism: lessons from novel glycogen phosphorylase inhibitors.

  2010cites this paper
• Synthesis and biological activity of naturally occurring α-glucosidase inhibitors.

  2010cites this paper
• Synthesis of 1-(D-glucopyranosyl)-1,2,3-triazoles and their evaluation as glycogen phosphorylase inhibitors.

  2010cites this paper
• Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723

  2010cites this paper
• Pharmacological manipulation of brain glycogenolysis as a therapeutic approach to cerebral ischemia.

  2010cites this paper
• Small molecules from natural sources, targeting signaling pathways in diabetes.

  2010cites this paper
• Anti‐diabetic effect of standardized extract of Potentilla discolor Bunge and identification of its active components

  2009cites this paper
• Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase.

  2009cites this paper
• Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.

  2009cites this paper
• Glycogen phosphorylase inhibitory effects of 2-oxo-1,2-dihydropyridin-3-yl amide derivatives.

  2009cites this paper
• Glycogen phosphorylase a inhibitors with a phenethylphenylphthalimide skeleton derived from thalidomide-related alpha-glucosidase inhibitors and liver X receptor antagonists.

  2009cites this paper
• Synthesis of new modified truncated peptides and inhibition of glycogen phosphorylase

  2009cites this paper
• Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.

  2009cites this paper
• Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase.

  2009cites this paper
• Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.

  2009cites this paper
• Hepatic 11 beta-hydroxysteroid dehydrogenase 1 involvement in alterations of glucose metabolism produced by acidotic stress in rat

  2009cites this paper
• Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.

  2009cites this paper
• Recent and emerging anti‐diabetes targets

  2009cites this paper
• Probing multivalency for the inhibition of an enzyme: glycogen phosphorylase as a case study

  2009cites this paper
• Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.

  2008cites this paper
• Molecular Recognition of the Protein Phosphatase 1 Glycogen Targeting Subunit by Glycogen Phosphorylase*

  2008cites this paper
• New inhibitors of glycogen phosphorylase as potential antidiabetic agents.

  2008cites this paper
• Evaluation of novel hyphodermin derivatives as glycogen phosphorylase a inhibitors.

  2008cites this paper
• Advances in glycogen phosphorylase inhibitor design.

  2008cites this paper
• Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.

  2008cites this paper
• Structural glycobiology: A game of snakes and ladders

  2008cites this paper
• Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitors.

  2008cites this paper
• Efficient synthesis from d-lyxonolactone of 2-acetamido-1,4-imino-1,2,4-trideoxy-l-arabinitol LABNAc, a potent pyrrolidine inhibitor of hexosaminidases

  2007cites this paper
• New hepatic targets for glycaemic control in diabetes.

  2007cites this paper
• Maslinic acid reduces blood glucose in KK-Ay mice.

  2007cites this paper
• Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.

  2007cites this paper
• Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors.

  2007influential citation
• Structural glycobiology : A game of snakes and ladders

  2007cites this paper